Cybin (NASDAQ:HELP) Price Target Raised to $62.00

Cybin (NASDAQ:HELP) had its price target lifted by TD Cowen from $8.00 to $62.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Wells Fargo & Company assumed coverage on shares of Cybin in a report on Monday, July 27th. They set an “overweight” rating and a $16.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Cybin currently has a consensus rating of “Buy” and an average price target of $48.60.

Cybin Stock Performance

HELP stock opened at $12.59 on Thursday. Cybin has a 52 week low of $3.76 and a 52 week high of $12.95. The company has a market capitalization of $919.83 million, a PE ratio of -4.17 and a beta of 0.55. The company’s 50-day simple moving average is $7.82 and its 200 day simple moving average is $6.24.

Cybin (NASDAQ:HELP) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). On average, analysts forecast that Cybin will post -3.17 EPS for the current year.

Institutional Trading of Cybin

Large investors have recently modified their holdings of the stock. Millennium Management LLC increased its position in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after purchasing an additional 959,448 shares during the period. Pale Fire Capital SE bought a new stake in Cybin during the second quarter worth about $1,015,000. Bank of America Corp DE lifted its position in Cybin by 66.8% during the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after purchasing an additional 11,790 shares during the period. AXQ Capital LP bought a new stake in Cybin during the second quarter worth about $75,000. Finally, Osaic Holdings Inc. grew its stake in Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after buying an additional 2,400 shares in the last quarter. 17.94% of the stock is owned by institutional investors and hedge funds.

Cybin News Roundup

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: TD Cowen raised its price target for Cybin from $8 to $62—nearly eight times higher—and upgraded the stock to “buy.” The target implies substantial potential upside from recent trading levels, providing the main bullish catalyst for HELP. HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
• Positive Sentiment: HC Wainwright improved its estimates for several periods, including fiscal 2027 EPS to a loss of $2.78 from a loss of $2.96, fiscal 2029 EPS to a loss of $1.09 from a loss of $1.20, fiscal 2030 EPS to positive $0.62 from $0.36, and fiscal 2031 EPS to positive $3.78 from $3.23. These revisions indicate stronger expected profitability in the outer years.
• Positive Sentiment: HC Wainwright also raised its quarterly EPS forecasts for the second and third quarters of fiscal 2027 and modestly improved estimates for the fourth quarter of fiscal 2027 and first quarter of fiscal 2028.
• Neutral Sentiment: The analyst’s projections still show significant losses in the near and medium term, with estimated fiscal 2028 EPS of negative $2.19 and fiscal 2029 EPS of negative $1.09. The bullish case therefore depends heavily on successful development, regulatory progress and eventual commercialization of Cybin’s therapies.
• Negative Sentiment: HC Wainwright lowered several forecasts, including fiscal 2028 EPS to a loss of $2.19 from a loss of $2.09 and selected 2028 quarterly estimates. Cybin’s latest reported quarter also missed earnings expectations, highlighting continued execution and cash-burn risks.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.